You may have seen some media coverage on The Project this week on the need for access to Continuous Glucose Monitors (CGMs) and its funding for adults over 21.
JDRF Australia is strongly supportive of this need and has been a long-term and passionate advocate for the benefits of CGM for all people living with type 1 diabetes. JDRF, along with Diabetes Australia, the Australian Diabetes Educators Association (ADEA) the Australasian Paediatric Endocrine Group (APEG) and the Australian Diabetes Society (ADS) were part of a broad-based advocacy campaign that helped secure support for the current CGM program for young Australians.
But we know that isn’t the end, and we want all people with type 1 diabetes to have access to whatever drugs, devices, and technologies they want and need, including but not limited to CGMs, and will continue to advocate in support of that.
Also, as an organisation with a strong research focus, we are leading an evaluation of the effectiveness of the Government’s current CGM access program to help build a case for increased access and support. We are also advocating with the help of many in the type 1 diabetes community to ensure that our Type 1 Diabetes Clinical Research Network (T1DCRN) is funded beyond its current commitments so we can continue to show the value and effectiveness of the next generation of technologies as a foundation for their eventual adoption and reimbursement. On the T1DCRN, we are playing a strong leadership role in research advocacy as you may have seen. No other organisation will drive the continuation of this critical part of Australia’s type 1 diabetes research landscape.
We support this campaign and any additional funding that will improve the lives of people living with type 1 diabetes. We know both research and access are needed to have a positive impact on people living with type 1 diabetes.